Abstract
Literature is lacking on the absorption of posaconazole when administrated through a percutaneous jejunostomy.
A 56 year old patient with a history of hypopharynx carcinoma who had underwent radiotherapy of the neck region, and who was fed through a jejunostomy was treated with Ambisome for a mucormycosis infection of the neck. As step down treatment, oral posaconazole suspension was administered through the jejunostomy at a dose of 200mg qds.
Posaconazole serum levels were measured on days 5 and 11, and were found to be subtherapeutic at 0.3 and 0.2 mg/L respectively.
Administration of posaconazole suspension through a jejunostomy tube should probably not be recommended.
A 56 year old patient with a history of hypopharynx carcinoma who had underwent radiotherapy of the neck region, and who was fed through a jejunostomy was treated with Ambisome for a mucormycosis infection of the neck. As step down treatment, oral posaconazole suspension was administered through the jejunostomy at a dose of 200mg qds.
Posaconazole serum levels were measured on days 5 and 11, and were found to be subtherapeutic at 0.3 and 0.2 mg/L respectively.
Administration of posaconazole suspension through a jejunostomy tube should probably not be recommended.
| Original language | English |
|---|---|
| Publication status | Published - 2 Feb 2016 |
| Event | Vereniging van Ziekenhuisapothekers - , Belgium Duration: 2 Feb 2016 → … |
Conference
| Conference | Vereniging van Ziekenhuisapothekers |
|---|---|
| Country/Territory | Belgium |
| Period | 2/02/16 → … |